Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose long-course peginterferon alfa-2b for HBV-related hepatocellular carcinoma
ChiCTR2100047874Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xinjiang Medical University
- Start
- Jul 2021
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of peginterferon alfa-2b in hepatocellular carcinoma (HCC) and hepatitis B (HBV) (6 arms), sponsored by First Affiliated Hospital of Xinjiang Medical University. Primary endpoint: Imaging examination of liver. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
hepatocellular carcinoma (HCC)hepatitis B (HBV)
Beyond the preview
Go deeper on ChiCTR2100047874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047874.